Ligand Pharmaceuticals | LGND - Interest Expense On Debt


Ligand Pharmaceuticals reported $910K in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Agenus USD 12.8M 7.89M Mar/2025
Amgen USD 653M 32M Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Baxter International USD 58M 14M Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Enviri Corporation USD 112.22M 83.4M Dec/2024
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Heron Therapeutics USD 500K 900K Sep/2024
Insmed USD 20.6M 217K Dec/2025
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Ligand Pharmaceuticals USD 910K 243K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Pacira USD 4.28M 456K Sep/2025
Pfizer USD 711M 59M Dec/2025
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023